Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. (NCT04775745)
A Phase I, Multicenter, Open-Label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects With Relapsed or Refractory B-cell Malignancies.
🩺 Plain-English Summary (8th-Grade Level)
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.
Who can join: Review the eligibility criteria below.
Location: Duke Univerisity — Durham, North Carolina
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Duke Univerisity — Durham, North Carolina
- University of Cincinnati — Cincinnati, Ohio
- Ohio State University — Columbus, Ohio
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (206) 335-3820
Email: yu@newavepharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in CLL/SLL
- Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies — Duarte, California
- Study of Epcoritamab as a Consolidation Therapy in CLL/SLL — Cincinnati, Ohio
- Global Trial in APG2575 for Patients With CLL/SLL — Tuscon, Arizona
- Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL — Duarte, California
Explore by condition: All CLL/SLL clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.